Since last year’s Supreme Court holding that naturally occurring DNA cannot be patented (as distinct from synthetic DNA created in the laboratory), Myriad Genetics has been busy. First, suing a number of its competitors for patent infringement on patents that withstood the Supreme Court case. Second, with the announcement of its European expansion and emphasis that it will rely less on patent protections and place greater reliance on the benefits stemming from its vast proprietary database of genetic mutations (and associated health outcomes). Genomics Law Report editor, John Conley, recently published an article on Myriad’s ex post facto strategy, entitled Myriad After Myriad: The Proprietary Data Dilemma impressing that Myriad’s approach, while doable, undermines certain principles and goals in medical research and health policy.